The use of immune checkpoint inhibitors (ICIs) dramatically changed the history of advanced non–small-cell lung cancer. The current knowledge on the mechanisms underlying resistance is still in ...

Tackling antibiotic resistance likely requires a multifaceted approach. Better and faster point-of-care testing, new treatments, and antimicrobial stewardship could hold promise for future control.

Dr Dietrich discusses patients acquiring and providers managing resistance to KRAS inhibition. If a patient is treated in second line with a KRAS inhibitor and starts to progress, the options are ...

Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies The following represents disclosure information provided by authors of this manuscript. All ...